Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)
Johan Vansteenkiste, Byoung Chul Cho(Yonsei University), Tõnu Vanakesa(North Estonia Medical Centre), Tommaso De Pas(European Institute of Oncology), M. Zieliński, M.S. Kim, Jacek Jassem(Gdańsk Medical University), Masahiro Yoshimura(Hyogo Prefectural Cancer Center), Jubrail Dahabreh(Athens Medical Center), Hironao Nakayama(Kanagawa Cancer Center), Libor Havel(Fakultní nemocnice Bulovka), Haruhiko Kondo(Kyorin University), Tetsuya Mitsudomi(Kindai University), Kostas Zarogoulidis(G. Papanikolaou General Hospital), Oleg Gladkov(Chelyabinsk Regional Clinical Oncology Center), Bart Spiessens(GlaxoSmithKline (Switzerland)), Vincent Brichard(GlaxoSmithKline (Switzerland)), C. Debruyne(GlaxoSmithKline (Switzerland)), P. Therasse(GlaxoSmithKline (Switzerland)), Nasser K. Altorki
Cited by 53
Abstract
Related Papers
No related papers found
Powered by citation graph analysis